Skip to main content

Table 6 Influence of different combined oral contraceptive formulations in the carbohydrate metabolism biomarkers of polycystic ovary syndrome

From: Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome

COC formulation

Number of studies

Before

Md (1st – 3rd)

After

Md (1st – 3rd)

∆

p*

Glucose (mg/dl)

 EE 35 μg / CPA 2 mg

12

86.6 (81.0–92.0)

85.6 (84.3–91.9)

−1.0

0.514

 EE 30 μg / DRSP 3 mg

10

84.4 (78.7–91.2)

85.7 (80.6–90.6)

+1.3

0.998

 EE 30 μg / CMA 2 μg

2

86.0(84.5–87.5)

81.8 (80.5–83.1)

−4.2

0.010

 EE 30 μg / DSG 75–150 μg

5

84.5 (81.3) – 88.9)

85.2 (81.9–88.0)

+0.7

0.892

Insulin (μUI/ml)

 EE 35 μg / CPA 2 mg

11

17.9 (10.8–22.8)

17.1 (10.0–18.6)

−0.8

0.213

 EE 30 μg / DRSP 3 mg

08

13.9 (11.3–18.1)

12.1 (10.1–18.5)

−1.8

0.865

 EE 30 μg / CMA 2 mg

03

7.3 (5.2–9.4)

7.8 (6.1–9.5)

+0.5

0.285

 EE 30 μg / DSG 75–150 μg

04

15.7 (13.0–19.0)

17.1 (13.1–22.1)

+1.4

0.144

 EE 30 μg / 180–250 μg NGM

02

8.9 (7.6–10.2)

9.1(7.2–11.0)

+0.2

0.788

C-peptide (mg/dl)

 EE 35 μg / CPA 2 mg

03

2.6 (2.0–3.2)

3.0 (2.9–3.9)

+0.4

0.179

 EE 30 μg / DRSP 3 mg

03

1.2 (0.7–1.7)

1.3 (0.7–1.9)

+0.1

0.654

 EE 30 μg / DSG 75–150 μg

02

1.6 (1.5–1.7)

2.4 (2.0–2.8)

+0.8

0.179

HOMA-IR

 EE 35 μg / CPA 2 mg

09

3.6 (2.0–4.4)

2.2 (1.8–3.9)

−1.4

0.213

 EE 30 μg / DRSP 3 mg

10

3.1 (2.2–3.7)

2.8 (2.5–3.8)

−0.3

0.593

 EE 30 μg / CMA 2 mg

03

1.6 (1.2–2.0)

1.6 (1.3–2.0)

0

0.592

 EE 30 μg / DSG 75–150 μg

03

3.0 (2.3–3.7)

2.6 (2.2–3.0)

−0.4

0.285

HbA1C (%)

 EE 35 μg / CPA 2 mg

04

5.0 (4.6–5.4)

5.1 (4.7–5.6)

+0.1

0.422

 EE 30 μg / DRSP 3 mg

02

3.5 (2.7–4.3)

3.5 (1.7–7.3)

0

0.653

  1. COC combined oral contraceptive, Md (1st – 3rd) median, first and third quartiles, HOMA-IR homeostatic model assessment for insulin resistance, HbA1C glycated hemoglobin, EE ethinylestradiol, CPA cyproterone acetate, DRSP drospirenone, CMA chlormadinone acetate, DSG desogestrel, NGM norgestimate
  2. p* Wilcoxon signed- ranks test